Azathioprine appears to improve disease course in early Crohn’s

Fire ant venom could be a surprising new treatment for psoriasis
December 7, 2017
Researchers may have discovered a cause of multiple sclerosis 
December 7, 2017
Show all

Azathioprine appears to improve disease course in early Crohn’s

In early Crohn’s disease, the medication azathioprine can improve symptoms.

Yun Qiu, from Sun Yat-sen University in China, and colleagues evaluated the impact of AZA on  progression in a cohort of 190  with early CD (disease duration ≤18 months) and no previous use of disease-modifying agents.

The researchers found that over a median follow-up of 57 months, 31 patients underwent abdominal surgeries, 48 patients were hospitalized, and 68 patients experienced clinical flares. The cumulative rate of remaining free of CD-related bowel , hospitalization, and flares after five years on AZA treatment was 0.65, 0.59, and 0.39, respectively. Prior bowel resection (hazard ratio [HR], 9.23; smoking (HR, 4), and hemoglobin <110 g/L at the time of initiation of AZA (HR, 4.36) were independent predictors of CD-related operations. AZA treatment duration >36 months (HR, 0.04) was associated with reduced CD-related operations.

“Prolonged use of AZA was associated with a more favorable disease course of early CD, evident as a lower risk of CD-related surgery,” conclude the authors.

Several authors disclosed financial ties to the pharmaceutical industry.

Read full article: Azathioprine appears to improve disease course in early Crohn’s

Read Full Article: Azathioprine appears to improve disease course in early Crohn’s

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.